About NRC

Neurapheresis™ Research Consortium

Collaborating to accelerate the development of novel therapies for underserved neurological conditions.

In 2017, Minnetronix Neuro and Duke University Medical Center founded the Neurapheresis™ Research Consortium, with a shared mission to bring together leading researchers and clinicians to accelerate development of Neurapheresis therapy for underserved neurological conditions. We believe that together we can improve outcomes for multiple patient populations suffering from diseases involving infectious, inflammatory and neurodegenerative agents affecting the central nervous system.
Working in tandem, Minnetronix and Duke University Medical Center bring more than two decades of product development expertise and world-class research capabilities to advance Neurapheresis Therapy into human clinical research, and ultimately into the clinic for multiple indications. The proprietary technology platform developed by Minnetronix Neuro, coupled with the clinical and scientific research facilities of Duke University Medical Center, uniquely position the NRC to accelerate the commercialization of a therapy designed to prevent secondary injury and enhance healing by eliminating disease-causing agents from the CSF.
By building an exceptional team of global disease and medical technology experts to advance research and develop truly novel therapies, the Neurapheresis Research Consortium will unite the world’s leading authorities on specific disease states and medical technology experts. In conjunction with organizations that support grant-based funding, the goal is to deliver meaningful solutions to patients suffering from debilitating and life-threatening neurological conditions.

How we operate

The NRC funds scientific and clinical research primarily by pursuing non-dilutive funding, with direct funding available on a case-by-case basis. We engage collaborators with sponsored research agreements or as consultants/subawards on federal grant applications (e.g., SBIR/STTR, R01).